BUFFALO, N.Y. — University at Buffalo neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication, often described as a wonder drug, ...
In my previous post, I shared my journey discovering that low-dose sublingual (LDSL) ketamine produces remarkable results in patients with treatment-resistant depression. Now, let's explore why lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results